Post-ECC 2015 Review and Analysis: New Immunotherapeutic Treatment Options for the Management of Patients with Bladder Cancer

Course Information

Therapautic Area: Oncology
Format(s): Webcast, Downloadable Transcript , Post Conference Review and Analysis
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: January 22, 2016 - January 21, 2017


Program Overview

This CME activity will focus on the essential sessions and new and emerging clinical data presented at the ECC pertaining to the management of patients with bladder cancer. The current science on immunotherapies, including CTLA-4 inhibitors, will be reviewed and presented to learners in a way that allows them to apply it in their practice. The newest therapeutic options for the treatment of bladder cacner will be analyzed. Robsust discussion along with data presentation will give physicians the ability to apply the most up-to-date therapeutic options whe developing treatment plans for their bladder cancer patients.

Target Audience

Oncologists, radiation oncologists, urologists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review the current science and clinical trial data for immunotherapies, including CTLA-­4 inhibitors, for patients with bladder cancer.
  2. Analyze the relevant data from ECC 2015 to apply the most up‐to-­date therapeutic options for the treatment of bladder cancer.


galsky headshotMatthew Galsky, MD
Associate Professor of Medicine
Hematology and Medical Oncology
Ichan School of Medicine at Mount Sinai
New York, NY



plimack headshotElizabeth Plimack, MD, MS
Associate Professor of Hematology/Oncology
Director of Genitourinary Clinical Research
Fox Chase Cancer Center
Temple Health
Philadelphia, PA



balar headshotArjun Balar, MD
Assistant Professor of Medicine
Division of Hematology & Oncology
New York University Perlmutter Cancer Center
NYU Langone Medical Center
New York, NY


Disclosure of Conflicts of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Matthew Galsky, MD Consultant/Advisor: Genetech, Inc.Grant/Research Support: Bristol-Myers Squibb Company; Merck & Co. IncStock Ownership: Dual Therapeutics
Elizabeth Plimack, MD, MS Consultant/Advisor: Acceleron Pharma; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Genentech, Inc;, Pfizer, Inc; Novartis Pharmaceuticals CorporationGrant/Research Support: Acceleron Pharma; AstraZeneca; Bristol-Myers Squibb Company; GlaxoSmithKline; Eli Lilly and Company; Merck & Co. Inc; Pfizer Inc
Arjun Balar, MD Consultant/Advisor: F. Hoffmann-La Roche Ltd; Genentech, Inc.Grant/Research Support: Merck & Co. Inc.

Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.Non-faculty

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.


For all CME inquiries or special needs, please contact